<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/256132-proteasome-inhibitors-and-methods-of-using-the-same by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 09:53:21 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 256132:PROTEASOME INHIBITORS AND METHODS OF USING THE SAME</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">PROTEASOME INHIBITORS AND METHODS OF USING THE SAME</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly or indirectly with proteasome activity.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>WO 2006/086600	PCT/US2006/004664<br>
PROTEASOME INHIBITORS AND METHODS OF USING THE SAME<br>
This application claims benefit of priority to U.S. Provisional Serial No.<br>
60/652,370 filed on February 11,2005, which is hereby incorporated by reference in<br>
its entirety.<br>
FIELD OF THE INVENTION<br>
The present invention relates to boronic acid and boronic ester compounds<br>
useful as proteasome inhibitors and modulation of apoptosis.<br>
BACKGROUND OF THE INVENTION<br>
The proteasome, (also refered to as multicatalytic protease (MCP),<br>
multicatalytic proteinase, multicatalytic proteinase complex, multicatalytic<br>
endopeptidase complex, 20S, 26S, or ingensin) is a large, multiprotein complex<br>
present in both the cytoplasm and the nucleus of all eukaryotic cells. It is a highly<br>
conserved cellular structure that is responsible for the ATP-dependent proteolysis of<br>
most cellular proteins (Tanaka, Biochem Biophy. Res. Commun., 1998, 247, 537). The<br>
26S proteasome consists of a 20S core catalytic complex that is capped at each end by<br>
a 19S regulatory subunit. The archaebacterial 20S proteasome contains fourteen<br>
copies of two distinct types of subunits, a and b, which form a cylindrical structure<br>
consisting of four stacked rings. The top and bottom rings contain seven:a-subunits<br>
each, while the inner rings contain seven b-subunits. The more complex eukaryotic<br>
20S proteasome is composed of about 15 distinct 20-30 kDa subunits and is<br>
characterized by three major activities with respect to peptide substrates. For example,<br>
the proteasome displays tryptic-, chymotryptic-, and peptidylglutamyl peptide-<br>
hydrolytic activities (Rivett, Biochem. J., 1993, 291, 1 and Orlowski, Biochemistry,<br>
1990, 29, 10289). Further, the proteasome has a unique active site mechanism which<br><br>
WO 2006/086600	PCT/US2006/004664<br>
is believed to utilize a threonine residue as the catalytic nucleophile (Seemuller, et al.,<br>
Science, 1995,268,579).<br>
The 26S proteasome is able to degrade proteins that have been marked by the<br>
addition of ubiquitin molecules. Typically, ubiquitin is attached to the e-amino groups<br>
of lysines in a multistep process utilizing ATP and El (ubiquitin activating) and E2<br>
(ubiquitin-conjugating) enzymes. Multi-ubiquitinated substrate proteins are<br>
recognized by the 26S proteasome and are degraded. The multi-ubiquitin chains are<br>
generally released from the complex and ubiquitin is recycled (Goldberg, et al.,<br>
Nature, 1992, 357, 375).<br>
Numerous regulatory proteins are substrates for ubiquitin dependent<br>
proteolysis. Many of these proteins function as regulators of physiological as well as<br>
pathophysiological cellular processes. Alterations in proteasome activity have been<br>
implicated in a number of pathologies including neurodegenerative diseases such as<br>
Parkinson's disease, Alzheimer's disease, as well as occlusion/ischaemia reperfusion<br>
injuries, and aging of the central nervous system.<br>
The ubiquitin-proteasome pathway also plays a role in neoplastic growth. The<br>
regulated degradation of proteins such as cyclins, CDK2 inhibitors, and tumor<br>
suppressors is believed to be important in cell cycle progression and mitosis. A known<br>
substrate of the proteasome is the tumor suppressor p53 which is involved in several<br>
cellular processes (see, e.g., Ko, L. J. Genes Dev., 1996,10, 1054). Tumor suppressor<br>
p53 has been shown to induce apoptosis in several haematopoietic cell lines (Oren,<br>
M., Semin. Cancer Biol, 1994, 5, 221). Induction of p53 leads to cell growth arrest in<br>
the Gl phase of the cell cycle as well as cell death by apoptosis. Tumor suppressor<br>
p53 degradation is known to be carried out via the ubiquitin-proteasome pathway, and<br>
disrupting p53 degradation by inhibition of the proteasome is a possible mode of<br>
inducing apoptosis.<br>
The proteasome is also required for activation of the transcription factor NF-<br>
KB by degradation of its inhibitory protein, IKB (Palombella, et al., Cell, 1994, 78,<br>
773). NF-KB has a role in maintaining cell viability through the transcription of<br>
2<br><br>
WO 2006/086600	PCT/US2006/004664<br>
inhibitors of apoptosis. Blockade of NF-KB activity has been demonstrated to make<br>
cells more susceptible to apoptosis.<br>
Several inhibitors of the proteolytic activity of the proteasome have been<br>
reported. See, for example, Kisselev, et al., Chemistry &amp; Biology, 2001, 8, 739.<br>
Lactacystin is a Streptomyces metabolite that specifically inhibits the proteolytic<br>
activity of the proteasome complex (Fenteany, et al., Science, 1995, 268, 726). This<br>
molecule is capable of inhibiting the proliferation of several cell types (Fenteany, et<br>
al., Proc. Natl. Acad. Sci. USA, 1994, 91, 3358). It has been shown that lactacystin<br>
binds irreversibly, through its P-lactone moiety, to a threonine residue located at the<br>
amino terminus of the p~ subunit of the proteasome.<br>
Peptide aldehydes have been reported to inhibit the chymotrypsin-like activity<br>
associated with the proteasome (Vinitsky, et al., Biochemistry, 1992, 31, 9421;<br>
Tsubuki, et al., Biochem. Biophys. Res. Commun., 1993, 196, 1195; and Rock, et al.,<br>
Cell, 1994, 78, 761). Dipeptidyl aldehyde inhibitors that have IC50 values in the 10-<br>
100 nM range in vitro (Iqbal, M., et al., J. MedChem., 1995, 38, 2276) have also been<br>
reported. A series of similarly potent in vitro inhibitors from a.-ketocarbonyl and<br>
boronic ester derived dipeptides has also been reported (Iqbal, et al., Bioorg. Med.<br>
Chem. Lett., 1996, 6, 287, U.S. Pat. Nos. 5,614,649; 5,830,870; 5,990,083; 6,096,778;<br>
6,310,057; U.S. Pat. App. Pub. No. 2001/0012854, and WO 99/30707).<br>
N-terminal peptidyl boronic ester and acid compounds have been reported<br>
previously (U.S. Pat. Nos. 4,499,082 and 4,537,773; WO 91/13904; Kettner, et al., J.<br>
Biol Chem., 1984, 259(24), 15106). These compounds are reported to be inhibitors of<br>
certain proteolytic enzymes. N-terminal tri-peptide boronic ester and acid compounds<br>
have been shown to inhibit the growth of cancer cells (U.S. Pat. No. 5,106,948). A<br>
broad class of N-terminal tri-peptide boronic ester and acid compounds and analogs<br>
thereof has been shown to inhibit renin (U.S. Pat. No. 5,169,841).<br>
Various inhibitors of the peptidase activities of the proteasome have also been<br>
reported. See, e.g., Dick, et al., Biochemistry, 1991, 30, 2725; Goldberg, et al.,<br>
Nature, 1992, 357, 375; Goldberg, Eur. J. Biochem., 1992, 203, 9; Orlowski,<br>
Biochemistry, 1990, 29,10289; Rivett, et al, Archs. Biochem. Biophys., 1989,218, 1;<br>
3<br><br>
WO 2006/086600	PCT/US2006/004664<br>
Rivett, et al., J. Biol. Chem., 1989, 264, 12215; Tanaka, et al., New Biol, 1992, 4, 1;<br>
Murakami, et al., Proc. Nad. Acad Sci. USA, 1986, 83, 7588; Li et al., Biochemistry,<br>
1991, 30, 9709; Goldberg, Eur. J. Biochem., 1992, 203, 9; and Aoyagi, et al.,<br>
Proteases and Biological Control, Cold Spring Harbor Laboratory Press (1975), pp.<br>
429-454.<br>
Stein et al., U.S. patent application Ser. No. 08/212,909, filed March 15,1994,<br>
report peptide aldehydes useful for reducing in an animal both the rate of loss of<br>
muscle mass and the rate of intracellular protein breakdown. The compounds are also<br>
said to reduce the rate of degradation of p53 protein in an animal. Palombella, et al.,<br>
WO 95/25533, report the use of peptide aldehydes to reduce the cellular content and<br>
activity of NF-KB in an animal by contacting cells of the animal with a peptide<br>
aldehyde inhibitor of proteasome function or ubiquitin conjugation. Goldberg and<br>
Rock, WO 94/17816, report the use of proteasome inhibitors to inhibit MHC-I antigen<br>
presentation. Stein, et al., U.S. Pat. No. 5,693,617 report peptidyl aldehyde<br>
compounds as proteasome inhibitors useful for reducing the rate of degradation of<br>
protein in an animal. Inhibition of the 26S and 20S proteasome by indanone<br>
derivatives and a method for inhibiting cell proliferation using indanone derivatives<br>
are reported by Lum et al., U.S. Pat. No. 5,834,487. Alpha-ketoamide compounds<br>
useful for treating disorders mediated by 20S proteasome in mammals are reported in<br>
Wang et al., U.S. Pat. No. 6,075,150. France, et al., WO 00/64863, report the use of<br>
2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors.<br>
Carboxylic acid derivatives as proteasome inhibitors are reported by Yamaguchi et<br>
al., EP 1166781. Ditzel, et al., EP 0 995 757 report bivalent inhibitors of the<br>
proteasome. 2-Aminobenzylstatine derivatives that inhibit non-covalently the<br>
chymotrypsin-like activity of the 20S proteasome have been reported by Garcia-<br>
Echeverria, et al., Bioorg. Med. Chem. Lett., 2001,11, 1317.<br>
Some further proteasome inhibitors can contain boron moieties. For example,<br>
Drexler et al., WO 00/64467, report a method of selectively inducing apoptosis in<br>
activated endothelial cells or leukemic cells having a high expression level of c-myc<br>
by using tetrapeptidic boronate containing proteasome inhibitors. Furet et al., WO<br>
4<br><br>
WO 2006/086600	PCT/US2006/004664<br>
02/096933	report	2-[[N-(2-amino-3-(heteroaryl	or<br>
aryl)propionyl)aminoacyl]amino]alkylboronic acids and esters for the therapeutic<br>
treatment of proliferative diseases in warm-blooded animals. U.S. Pat. Nos.<br>
6,083,903; 6,297,217; 5,780454; 6,066,730; 6,297,217; 6,548,668; U.S. Patent<br>
Application Pub. No. 2002/0173488; and WO 96/13266 report boronic ester and acid<br>
compounds and a method for reducing the rate of degradation of proteins. A method<br>
for inhibiting viral replication using certain boronic acids and esters is also reported in<br>
U.S. Pat. No. 6,465,433 and WO 01/02424. Pharmaceutically acceptable<br>
compositions of boronic acids and novel boronic acid anhydrides and boronate ester<br>
compounds are reported by Plamondon, et al., U.S. Patent Application Pub. No.<br>
2002/0188100. A series of di- and tripeptidyl boronic acids are shown to be inhibitors<br>
of 20S and 26S proteasome in Gardner, et al., Biochem. J., 2000, 346,447.<br>
Other boron-containing peptidyl and related compounds are reported in U.S.<br>
Pat. Nos. 5,250,720; 5,242,904; 5,187,157; 5,159,060; 5,106,948; 4,963,655;<br>
4,499,082; and WO 89/09225, WO/98/17679, WO 98/22496, WO 00/66557, WO<br>
02/059130, WO 03/15706, WO 03/59898, WO 96/12499, WO 95/20603, WO<br>
95/09838, WO 94/25051, WO 94/25049, WO 94/04653, WO 02/08187, EP 632026,<br>
and EP 354522. U.S. Pat. App. Ser. Nos. 10/918,664 and 10/918,610, the disclosures<br>
of each of which are incorporated herein by reference in their entireties, further report<br>
additional boron-containing peptidyl-like proteasome inhibitors.<br>
A great interest exists, as evidenced by the above references, in drugs which<br>
can modulate proteasome activity. For example, molecules capable of inhibiting<br>
proteasome activity can arrest or delay cancer progression by interfering with the<br>
ordered degradation of cell cycle proteins or tumor suppressors. Accordingly, there is<br>
an ongoing need for new and/or improved inhibitors of proteasome.<br>
SUMMARY OF THE INVENTION<br>
The present invention is directed to novel boronic acid and boronic ester<br>
compounds useful as proteasome inhibitors and modulation of apoptosis. The subject<br>
5<br><br>
WO 2006/086600	PCT7US2006/004664<br>
invention also comprises methods for inhibition of multicatalytic protease ("MCP")<br>
associated with certain disorders, including the treatment of muscle wasting disorders.<br>
In one embodiment are provided compounds having Formula (I):<br><br>
wherein constituent members are defined infra, as well as preferred constituent<br>
members.<br>
In another embodiments, the present invention provides a compound which is<br>
a boronic anhydride of a compound of Formula (I), such as a cyclic boronic<br>
anhydride.<br>
In another embodiment the present invention provides a pharmaceutical<br>
composition comprising a compound of Formula (I) and a pharmaceutically<br>
acceptable carrier.<br>
In another embodiment the present invention provides a method of inhibiting<br>
activity of proteasome comprising contacting a compound of Formula (I) with the<br>
proteasome.<br>
In another embodiment the present invention provides a method of treating<br>
cancer comprising administering to a mammal having or predisposed to the cancer a<br>
therapeutically effective amount of a compound of Formula (I).<br>
In another embodiment the present invention provides a method of treating<br>
cancer comprising administering to a mammal having or predisposed to the cancer a<br>
therapeutically effective amount of a compound of Formula (I), and wherein the<br>
cancer is selected from skin, prostate, colorectal, pancreas, kidney, ovary, mammary,<br>
liver, tongue, lung, and smooth muscle tissue.<br>
In another embodiment the present invention provides a method of treating<br>
cancer comprising administering to a mammal having or predisposed to the cancer a<br>
therapeutically effective amount of a compound of Formula (I),   and wherein said<br>
6<br><br>
WO 2006/086600	PCT/US2006/004664<br>
cancer is selected from leukemia, lymphoma, non-Hodgkin lymphoma, myeloma, and<br>
multiple myeloma.<br>
In another embodiment the present invention provides a method of treating<br>
cancer comprising administering to a mammal having or predisposed to the cancer a<br>
therapeutically effective amount of a compound of Formula (I) in combination with<br>
one or more antitumor or anticancer agent and/or radiotherapy.<br>
In another embodiment the present invention provides a method of inhibiting<br>
activity of transcription factor NF-KB comprising contacting IKB, the inhibitor of<br>
transcription factor NF-KB, with a compound of Formula (I).<br>
In another embodiment, the present invention provides a compound of<br>
Formula (I) for use in therapy.<br>
In another embodiment, the present invention provides use of a compound of<br>
Formula (I) for the manufacture of a medicament for the treatment of cancer.<br>
These and other features of the compounds will be set forth in expanded form<br>
as the disclosure continues.<br>
DETAILED DESCRIPTION<br>
The present invention provides, inter alia, compounds that can inhibit<br>
proteasome activity and be used for the treatment of diseases or disorders related to<br>
proteasome activity. Compounds of the invention include compounds of Formula (I):<br><br>
or pharmaceutically acceptable salt forms thereof, wherein:<br>
Q is -B(ORB)2, boronic acid, or a cyclic boronic ester wherein said cyclic<br>
boronic ester contains from 2 to 20 carbon atoms, and, optionally, a heteroatom which<br>
can be N, S, or O;<br>
7<br><br>
WO 2006/086600	PCT/US2006/004664<br>
RB is, independently, H, C1-4alkyl, cycloalkyl, cycloalkylalkyl, aryl, or<br>
aralkyl;<br>
Z is -CH(OH)CH3 or-CHaNR1aR1;<br>
Hy is a 5- or 6- membered heterocyclic group optionally fused with an aryl or<br>
heteroaryl group, wherein said 5- or 6-membered heterocyclic group contains at least<br>
one ring-forming N atom, and wherein said Hy is optionally substituted by 1,2 or 3<br>
R4;<br>
R1 is H, C1-10 alkyl, carbocyclyl, heterocyclyl, C1-10 alkyl-C(=O)-, C2-10<br>
alkenyl-C(=O)-, C2-10 alkynyl-C(=O)-, carbocyclyl-C(=O)-, heterocyclyl-C(=O)-,<br>
carbocyclylalkyl-C(=O)-, heterocyclylalkyl-C(=0)-, C1-10  alkyl-S(=O)2-, carbocyclyl-<br>
S(=O)2-, heterocyclyl-S(=O)2-, carbocyclylalkyl-S(=O)2-, heterocyclylalkyl-S(=O)2-,<br>
C1-C10 alkyl-NHC(=O)-, carbocyclyl-NHC(=O)-, heterocyclyl-NHC(=O)-,<br>
carbocyclylalkyl-NHC(=0)-, heterocyclylalkyl-NHC(=O)-, C1-C10 alkyl-OC(=O)-,<br>
carbocyclyl-OC(=O)-,heterocyclyl-OC(=O)-, carbocyclylalkyl-OC(=0)-,<br>
heterocyclylalkyl-OC(=O)-, C1-10 alkyl-NH-C(=O)-NHS(=O)2-, carbocyclyl-NH-<br>
C(=O)-NHS(=O)2-, heterocyclyl-NH-C(=O)-NHS(=O)2-5 C1-10 alkyl-S(=O)2-NH-<br>
C(O)-, carbocyclyl-S(=O)2-NH-C(=O)-, heterocyclyl-S(=O)2-NH-C(=O)-, or an<br>
amino protecting group; wherein R1 is optionally substituted with 1, 2 or 3<br>
substituents selected from C1-6 alkyl, C2-6 alkenyl, C2_6 alkynyl, F, Cl, Br, I, C1-4 <br>
haloalkyl, -NH2, -NHR2, -N(R2)2, -N3, -NO2, -CN, -CNO, -CNS, -C(=O)OR2, -<br>
C(=O)R2, -OC(=O)R2, -N(R2)C(=O)R2, -N(R2)C(=O)OR2, -C(=O)N(R2)2, ureido, -<br>
OR2, -SR2, -S(=O)-(C1-6 alkyl), -S(=O)2-(C1-6 alkyl), -S(=O)-aryl, -S(=O)2-aryl, -<br>
S(=O)2-N(R2)2; carbocyclyl optionally substituted witli 1,2, 3,4 or 5 R3; and<br>
heterocyclyl optionally substituted with 1, 2, 3,4, or 5 R3;<br>
Rla is H; or Rla and R1 together with the N atom to which they are attached<br>
form a 4-, 5-, 6- or 7-memebered heterocyclyl group optionally substituted with 1, 2,<br>
or 3 R3;<br>
R2 is, independently, H or C1-6  alkyl;<br>
alternatively, two R2 may be combined, together with the N atom to which<br>
they are attached, to form a 5-, 6- or 7-membered heterocyclic group;<br>
8<br><br>
WO 2006/086600	PCT/US2006/004664<br>
R3 is, independently, selected from C1-4alkyl, C2-4 alkenyl, C2-4 alkynyl,<br>
phenyl, halo, haloalkyl, alkoxy, thialkoxy, amino, alkylamino, dialkylamino,<br>
carboxyl, alkyl-OC(=O)-, alkyl-C(=O)-, aryl-OC(=O)-, alkyl-OC(=O)NH-, aryl-<br>
OC(=O)NH-, alkyl-C(=O)NH-, alkyl-C(=O)O, (alkyl-O)r-alkyl,'HO-(alkyl-O)r-<br>
alkyl-, -OH, -SH, -CN, -N3, -CNO, -CNS, alkyl-S(=O)-, alkyl-S(=O)2-, H2NS(=O)-,<br>
and H2NS(=O)2-;<br>
R4 is, independently, selected from C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, -<br>
OR4a, -SR4a, -CN, halo, haloalkyl, -NH2, -NH(alkyl), -N(alkyl)2, -NHC(=O)O-alkyl, -<br>
NHC(=O)alkyl, -COOH, -C(=O)O-alkyl, -C(=O)alkyl, -C(O)H, -S(=O)-alkyl, -<br>
S(=O)2-alkyl, -S(=O)-atyl, -S(=O)2-aryl, carbocyclyl optionally substituted with 1,2<br>
or 3 R5, and heterocyclyl optionally substituted with 1, 2 or 3 R5;<br>
R4a is H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, carbocyclyl or<br>
heterocyclyl;<br>
R5 is, independently, selected from C1-10  alkyl, C2-10 alkenyl, C2-10 alkynyl,<br>
phenyl,<br>
halo, haloalkyl, alkoxy, thialkoxy, amino, alkylamino, dialkylamino, carboxyl, alkyl-<br>
OC(=O)-, alkyl-C(=O)-, aryl-OC(=O)-, alkyl-OC(=O)NH-, aryl-OC(=O)NH-, alkyl-<br>
C(=O)NH-, alkyl-C(=O)O-, (ilkyl-O)r-alkyl,HO-(alkyl-O)r-alkyl-OH, -SH, -CN, -<br>
N3, -CNO, -CNS, alkyl-S(=O)-, aIkyI-S(=O)2-, H2NS(=O)-, and H2NS(=O)2-;<br>
9<br>
with the proviso that when Z is -CH(OH)CH3 and Q is<br><br><br>
WO 2006/086600	PCT/US2006/004664<br>
In some embodiments, Q is boronic acid (B(OH)2) or a cyclic boronic ester<br>
wherein said cyclic boronic ester contains from 6 to 10 carbon atoms and contains at<br>
least one cycloalkyl moiety.<br>
In some embodiments, Q is B(OH)2 or pinanediol boronic ester.<br>
In some embodiments, Q is pinanediol boronic ester.<br>
In some embodiments, Z is -CH(OH)CH3.<br>
In some embodiments, Z is -CH2NRlaR1.<br>
In some embodiments, Z is -CH2NHR1.<br>
In some embodiments, Z is -CH2NHR1 and R1 is carbocyclyl-C(=O)- or<br>
carbocyclyl-S(=O)2-, each optionally substituted with 1,2 or 3 substituents selected<br>
from C1-16 alkyl, C2-6 alkenyl, C2-6 alkynyl, F, Cl, Br, I, C1-4  haloalkyl, -NH2, -NHR2, -<br>
N(R2)2, -N3, -NO2, -CN, -CNO, -CNS, -C(=O)OR2, -C(=O)R2, -OC(=O)R2, -<br>
N(R2)C(=O)R2, -N(R2)C(=O)OR2, -C(=O)N(R2)2, ureido, -OR2, -SR2, -S(=O)-(C1-6 <br>
alkyl), -S(=O)2-(C1-6  alkyl), -S(=O)-aryl, -S(=O)2-aryl, -S(=O)2-N(R2)2; carbocyclyl<br>
optionally substituted with 1,2, 3,4 or 5 R3; and heterocyclyl optionally substituted<br>
with 1,2, 3, 4, or 5 R3.<br>
In some embodiments, Z is -CH2NHR1 and R1 is aryl-C(=O)- or aryl-S(=O)2-<br>
, each optionally substituted with 1,2 or 3 substituents selected from C1-6  alkyl, F, Cl,<br>
Br, I, C1-4  haloalkyl, carbocyclyl optionally substituted with 1, 2, 3, 4 or 5 R3 and<br>
heterocyclyl optionally substituted with 1,2, 3,4, or 5 R3.<br>
In some embodiments, Z is -CH2NHR1 and R1 is phenyl-C(=O)- or phenyl-<br>
S(=O)2-, each optionally substituted with C1-4 alkyl, F, Cl, Br, I, or aryl.<br>
In some embodiments, R1 is aryl-C(=O)- or aryl-S(=O)2-, each optionally<br>
substituted with 1, 2 or 3 substituents selected from C1-6 alkyl, F, Cl, Br, I, C1-4<br>
haloalkyl, carbocyclyl optionally substituted with 1,2, 3,4 or 5 R3 and heterocyclyl<br>
optionally substituted with 1,2, 3,4, or 5 R3.<br>
In some embodiments, R1 is aryl-C(=O)- optionally substituted with 1,2 or 3<br>
substituents selected from C1-6 alkyl, F, Cl, Br, I, and C1-4 haloalkyl.<br>
In some embodiments, R1 is phenyl-C(=O)- optionally substituted with 1,2 or<br>
3 substituents selected from C1-6 alkyl, F, Cl, Br, I, and C1-4 haloalkyl.<br>
10<br><br>
WO 2006/086600	PCT/US2006/004664<br>
In some embodiments, R1 is -CO-(4-methyIphenyl).<br>
In some embodiments, R1 is optionally substituted with 1 or 2 substituents.<br>
In some embodiments, R1 is optionally substituted with 1 substituent.<br>
In some embodiments, R1 is substituted with 1 substituent.<br>
In some embodiments, R1 is substituted with C1-6alkyl.<br>
In some embodiments, R1 is substituted with methyl.<br>
In some embodiments, Hy is pyridyl, N-oxopyridyl, pyrimidinyl, pyrazinyl,<br>
imidazolyl, thiazolyl, oxazolyl, pyrrolyl, pyrazolyl, quinolinyl, isoquinolinyl,<br>
quinoxalinyl, indolyl, quinazolinyl, benzoimidazolyl, benzothiazolyl, or benzoxazolyl,<br>
each optionally substituted by 1,2 or 3 R4.<br>
In some embodiments, Hy is pyridyl, N-oxopyridyl, pyrimidinyl, pyrazinyl,<br>
thiazolyl, pyrazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, or indolyl, each<br>
optionally substituted by 1, 2 or 3 R4.<br>
In some embodiments, Hy is pyridyl, N-oxopyridyl, pyrimidinyl, pyrazinyl,<br>
thiazolyl, pyrazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, or indolyl, each<br>
optionally substituted by 1 or 2 C1-8 alkyl, carbocyclyl optionally substituted with 1, 2<br>
or 3 R5, or heterocyclyl optionally substituted with 1,2 or 3 R5.<br>
In some embodiments, Hy is pyridyl, N-oxopyridyl, pyrimidinyl, pyrazinyl,<br>
thiazolyl, pyrazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, or indolyl, each<br>
optionally substituted by 1 or 2 methyl, ethyl, propyl, butyl, aryl optionally substituted<br>
with 1,2 or 3 R5, or heteroaryl optionally substituted with 1,2 or 3 R5.<br>
In some embodiments, Hy is pyridyl, pyrimidinyl, pyrazinyl, thiazolyl,<br>
pyrazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, or indolyl, each optionally<br>
substituted by 1 or 2 methyl, ethyl, propyl, butyl, aryl optionally substituted with 1,2<br>
or 3 R5, or heteroaryl optionally substituted with 1,2 or 3 R5.<br>
In some embodiments, Hy is pyrazine substituted by at least 1 or 2 R4,<br>
unsubstituted pyridin-2yl, pyridin-3-yl optionally substituted by 1 or 2 R4, pyridin-4-<br>
yl optionally substituted by 1 or 2 R4, N-oxo-pyridinyl optionally substituted by 1 or 2<br>
R4, pyrimidinyl optionally substituted by 1 or 2 R4, imidazolyl optionally substituted<br>
by 1 or 2 R4, thiazolyl optionally substituted by 1 or 2 R4, oxazolyl optionally<br>
11<br><br>
WO 2006/086600	PCT/US2006/004664<br>
substituted by 1 or 2 R4, pyrrolyl optionally substituted by I or 2 R4, pyrazolyl<br>
optionally substituted by 1 or 2 R4, quinolinyl optionally substituted by 1 or 2 R4,<br>
isoquinolinyl optionally substituted by 1 or 2 R4, quinoxalinyl optionally substituted<br>
by 1 or 2 R4, indolyl optionally substituted by 1 or 2 R4, quinazolinyl optionally<br>
substituted by 1 or 2 R4, benzoimidazolyl optionally substituted by 1 or 2 R4,<br>
benzothiazolyl optionally substituted by 1 or 2 R4, or benzoxazolyl optionally<br>
substituted by 1 or 2 R4.<br>
In some embodiments, Hy is pyrazine substituted by at least 1 or 2 R4,<br>
unsubstituted pyridin-2yl, pyridin-3-yl optionally substituted by 1 or 2 R4, pyridin-4-<br>
yl optionally substituted by 1 or 2 R4, N-oxo-pyridinyl optionally substituted by 1 or 2<br>
R4, pyrimidinyl optionally substituted by 1 or 2 R4, imidazolyl optionally substituted<br>
by 1 or 2 R , thiazolyl optionally substituted by 1 or 2 R4, oxazolyl optionally<br>
substituted by 1 or 2 R4, pyrrolyl optionally substituted by 1 or 2 R4, pyrazolyl<br>
optionally substituted by 1 or 2 R4, quinolinyl optionally substituted by 1 or 2 R4,<br>
isoquinolinyl optionally substituted by 1 or 2 R4, quinoxalinyl optionally substituted<br>
by 1 or 2 R4, indolyl optionally substituted by 1 or 2 R4, quinazolinyl optionally<br>
substituted by 1 or 2 R4, benzoimidazolyl optionally substituted by 1 or 2 R4,<br>
benzothiazolyl optionally substituted by 1 or 2 R4, or benzoxazolyl optionally<br>
substituted by 1 or 2 R4, wherein R4 is C1-6alkyl, aryl or heterocyclyl.<br>
In some embodiments, Hy is pyrazine substituted by at least 1 or 2 R4,<br>
unsubstituted pyridin-2yl, pyridin-3-yl optionally substituted by 1 or 2 R4, pyridin-4-<br>
yl optionally substituted by 1 or 2 R4, N-oxo-pyridinyl optionally substituted by 1 or 2<br>
R4, pyrimidinyl optionally substituted by 1 or 2 R4, imidazolyl optionally substituted<br>
by 1 or 2 R4, thiazolyl optionally substituted by 1 or 2 R4, pyrazolyl optionally<br>
substituted by 1 or 2 R4, quinolinyl optionally substituted by 1 or 2 R4, isoquinolinyl<br>
optionally substituted by 1 or 2 R4, quinoxalinyl optionally substituted by 1 or 2 R4, or<br>
indolyl optionally substituted by 1 or 2 R4.<br>
In some embodiments, Hy is pyrazine substituted by at least 1 or 2 R4,<br>
unsubstituted pyridin-2yl, pyridin-3-yl optionally substituted by 1 or 2 R4, pyridin-4-<br>
yl optionally substituted by 1 or 2 R4, N-oxo-pyridinyl optionally substituted by 1 or 2<br>
12<br><br>
WO 2006/086600	PCT/US2006/004664<br>
R4, pyrimidinyl optionally substituted by 1 or 2 R4, imidazolyl optionally substituted<br>
by 1 or 2 R4, thiazolyl optionally substituted by 1 or 2 R4, pyrazolyl optionally<br>
substituted by 1 or 2 R4, quinolinyl optionally substituted by 1 or 2 R4, isoquinolinyl<br>
optionally substituted by 1 or 2 R4, quinoxalinyl optionally substituted by 1 or 2 R4, or<br>
indolyl optionally substituted by 1 or 2 R4, wherein R4 is C1-6 alkyl, aryl or<br>
heterocyclyl.<br>
In some embodiments, Hy is pyrazine substituted by at least 1 or 2 R4,<br>
unsubstituted pyridin-2yl, pyridin-3-yl optionally substituted by 1 or 2 R4, pyridin-4-<br>
yl optionally substituted by 1 or 2 R4, pyrimidinyl optionally substituted by 1 or 2 R4,<br>
imidazolyl optionally substituted by 1 or 2 R4, thiazolyl optionally substituted by 1 or<br>
2 R4, pyrazolyl optionally substituted by 1 or 2 R4, quinolinyl optionally substituted<br>
by 1 or 2 R4, isoquinolinyl optionally substituted by 1 or 2 R4, quinoxalinyl optionally<br>
substituted by 1 or 2 R4, or indolyl optionally substituted by 1 or 2 R4, wherein R4 is<br>
C1-6 alkyl, aryl or heterocyclyl.<br>
13<br>
In some embodiments, Hy is selected from:<br><br><br>
WO 2006/086600	PCT/US2006/004664<br><br>
In some embodiments, Rla is H.<br>
In some embodiments, RB is H.<br>
In some embodiments, R4 is unsubstituted.<br>
In some embodiments, R is methyl, ethyl, propyl, butyl, aryl optionally<br>
substituted with 1,2 or 3 R5, or heteroaryl optionally substituted with 1, 2 or 3 R5.<br>
In some embodiments, R4 is C1-6alkyl, aryl or heterocyclyl.<br>
In some embodiments, R4 is methyl, butyl, phenyl, thienyl, or morpholino.<br>
In some embodiments:<br>
14<br><br>
WO 2006/086600	PCT/US2006/004664<br>
Z is -CH(OH)CH3; and<br>
Hy is a 5- or 6- membered heterocyclic group optionally fused with an aryl or<br>
heteroaryl group, wherein said 5- or 6-membered heterocyclic group contains at least<br>
one ring-forming N atom, and wherein said Hy is optionally substituted by 1,2 or 3<br>
R4.<br>
In some embodiments:<br>
Zis-CH(OH)CH3;and<br>
Hy is pyridyl, N-oxopyridyl, pyrimidinyl, pyrazinyl, imidazolyl, thiazolyl,<br>
oxazolyl, pyrrolyl, pyrazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, indolyl,<br>
quinazolinyl, benzoimidazolyl, benzothiazolyl, or benzoxazolyl, each optionally<br>
substituted by 1,2 or 3 R4.<br>
In some embodiments,:<br>
Z is-CH2NHR1;<br>
Hy is a 5- or 6- membered heterocyclic group optionally fused with an aryl or<br>
heteroaryl group, wherein said 5- or 6-membered heterocyclic group contains at least<br>
one ring-forming N atom, and wherein said Hy is optionally substituted by 1, 2 or 3<br>
R4; and<br>
R1 is carbocyclyl-C(=O)- or carbocyclyl-S(=O)2-5 each optionally substituted<br>
with 1,2 or 3 substituents selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, F, Cl,<br>
Br, I, C1-4 haloalkyl, -NH2, -NHR2, -N(R2)2, -N3, -NO2, -CN, -CNO, -CNS, -<br>
C(=O)OR2, -C(=O)R2, -OC(=O)R2, -N(R2)C(=O)R2, -N(R2)C(=O)OR2, -<br>
C(=O)N(R2)2, ureido, -OR2, -SR2, -S(=O)-(C1-6 alkyl), -S(=O)2-(C1-6 alkyl), -S(=O)-<br>
aryl, -S(=O)2-aryl, -S(=O)2-N(R2)2; carbocyclyl optionally substituted with 1,2, 3, 4<br>
or 5 R3; and heterocyclyl optionally substituted with 1, 2, 3,4, or 5 R3.<br>
In some embodiments:<br>
Zis-CH2NHR1;<br>
15<br><br>
WO 2006/086600	PCT/US2006/004664<br>
Hy is pyridyl, N-oxopyridyl, pyrimidinyl, pyrazinyl, imidazolyl, thiazolyl,<br>
oxazolyl, pyrrolyl, pyrazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, indolyl,<br>
quinazolinyl, benzoimidazolyl, benzothiazolyl, or benzoxazolyl, each optionally<br>
substituted by 1, 2 or 3 R4; and<br>
Rl is carbocyclyl-C(=O)- or carbocyclyl-S(=O)2-, each optionally substituted<br>
with 1, 2 or 3 substituents selected from C1-6 alkyl, F, Cl, Br, I, C1-4 haloalkyl,<br>
carbocyclyl optionally substituted with 1,2, 3,4 or 5 R3, and heterocyclyl optionally<br>
substituted with 1,2, 3, 4, or 5 R3.<br>
In some embodiments, compounds of the invention include compounds of<br>
Formula (I)<br>
or pharmaceutically acceptable salt forms thereof, wherein:<br>
Q is -B(ORB)2, boronic acid, or a cyclic boronic ester wherein said cyclic<br>
boronic ester contains from 2 to 20 carbon atoms, and, optionally, a heteroatom which<br>
can be N, S, or O;<br>
RB is, independently, H, C1-4 alkyl, cycloalkyl, cycloalkylalkyl, aryl, or<br>
aralkyl;<br>
Z is -CH(OH)CH3 or -CH2NHR1;<br>
Hy is pyridyl, N-oxopyridyl, pyrimidinyl, pyrazinyl, imidazolyl, thiazolyl,<br>
oxazolyl, pyrrolyl, pyrazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, indolyl,<br>
quinazolinyl, benzoimidazolyl, benzothiazolyl, or benzoxazolyl, each optionally<br>
substituted by 1, 2 or 3 R4;<br>
R1 is carbocyclyl-C(=O)- or heterocyclyl-C(=O)-, each optionally substituted<br>
withl, 2 or 3 R3;<br>
R3 is, independently, selected from C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl,<br>
phenyl, halo, haloalkyl, alkoxy, thialkoxy, amino, alkylamino, dialkylamino,<br>
carboxyl, alkyl-OC(=O)-, alkyl-C(-O)-, aryl-0C(O)-, alkyl-OC(=O)NH-, aryl-<br>
OC(=O)NH-, alkyl-C(=O)NH-, alkyl-C(=O)O-, -OH, -SH, -CN, -N3, -CNO, -CNS,<br>
alkyl-S(=O)-, alkyl-S(=O)2-, H2NS(=O)-, and H2NS(=O)2-;<br>
R4 is, independently, selected from C1-6 alkyl, aryl and heterocyclyl;<br>
16<br><br>
WO 2006/086600	PCT/US2006/004664<br>
with the proviso that when Z is -CH(OH)CH3 and Q is<br><br>
In some embodiments, compounds of the invention include compounds of<br>
Formula (I)<br>
or pharmaceutically acceptable salt forms thereof, wherein:<br>
Q is -B(ORB)2, boronic acid, or a cyclic boronic ester wherein said cyclic<br>
boronic ester contains from 2 to 20 carbon atoms, and, optionally, a heteroatom which<br>
can be N, S, or O;<br>
RB is, independently, H, C1-4 alkyl, cycloalkyl, cycloalkylalkyl, aryl, or<br>
aralkyl;<br>
Z is -CH(OH)CH3 or -CH2NHR1;<br>
Hy is pyridyl, N-oxopyridyl, pyrimidinyl, pyrazinyl, imidazolyl, thiazolyl,<br>
oxazolyl, pyrrolyl, pyrazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, indolyl,<br>
quinazolinyl, benzoimidazolyl, benzothiazolyl, or benzoxazolyl, each optionally<br>
substituted by 1, 2 or 3 C1-6 alkyl, aryl or heterocyclyl;<br>
R1 is carbocyclyl-C(=0)- or heterocyclyl-C(=O)-, each optionally substituted<br>
withl, 2 or 3 R3;<br>
R3 is, independently, selected from C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl,<br>
phenyl, halo, haloalkyl, alkoxy, thialkoxy, amino, alkylamino, dialkylamino,<br>
carboxyl, alkyl-OC(=O)-; alkyl-C(=O)-, aryl-OC(=O)-, alkyl-OC(=O)NH-, aryl-<br>
17<br><br>
WO 2006/086600	PCT/US2006/004664<br>
OC(=O)NH-, alkyl-C(=O)NH-, alkyl-C(=O)O-, -OH, -SH, -CN, -N3, -CNO, -CNS,<br>
alkyl-S(=O)-, alkyl-S(=O)2-, H2NS(=O)-, and H2NS(=O)2-;<br>
R4 is, independently, selected from C1-6alkyl, aryl and heterocyclyl;<br>
with the proviso that when Z is -CH(OH)CH3 and Q is<br><br>
In some embodiments, compounds of the invention include compounds of<br>
Formula (I)<br>
or pharmaceutically acceptable salt forms thereof, wherein:<br>
Q is -B(ORB)2, boronic acid, or a cyclic boronic ester wherein said cyclic<br>
boronic ester contains from 2 to 20 carbon atoms, and, optionally, a heteroatom which<br>
can be N, S, or O;<br>
RB is, independently, H, C1-4 alkyl, cycloalkyl, cycloalkylalkyl, aryl, or<br>
aralkyl;<br>
Z is -CH(OH)CH3 or -CH2NHR1;<br>
Hy is pyridyl, N-oxopyridyl, pyrimidinyl, pyrazinyl, imidazolyl, thiazolyl,<br>
oxazolyl, pyrrolyl, pyrazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, indolyl,<br>
quinazolinyl, benzoimidazolyl, benzothiazolyl, or benzoxazolyl, each optionally<br>
substituted by 1,2 or 3 C l-6 alkyl, phenyl, thienyl or morpholino;<br>
R! is carbocyclyl-C(=O)- or heterocyclyl-C(=O)-, each optionally substituted<br>
with 1,2 or 3 R3;<br>
18<br><br>
WO 2006/086600	PCT/US2006/004664<br>
R3 is, independently, selected from C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl,<br>
phenyl, halo, haloalkyl, alkoxy, thialkoxy, amino, alkylamino, dialkylamino,<br>
carboxyl, alkyl-OC(=O)-, alkyl-C(=O)-, aryl-OC(=O)-, alkyl-OC(=O)NH-, aryl-<br>
OC(=O)NH-, alkyl-C(=O)NH-, alkyl-C(=O)O-, -OH, -SH, -CN, -N3, -CNO, -CNS,<br>
alkyl-S(=O)-, alkyl-S(=O)2-, H2NS(=O)-, and H2NS(=O)2-;<br>
R4 is, independently, selected from C1-6 alkyl, aryl and heterocyclyl;<br>
with the proviso that when Z is -CH(OH)CH3 and Q is<br><br>
In some embodiments, compounds of the invention include compounds of<br>
Formula (I)<br>
or pharmaceutically acceptable salt forms thereof, wherein:<br>
Q is -B(ORB)2, boronic acid, or a cyclic boronic ester wherein said cyclic<br>
boronic ester contains from 2 to 20 carbon atoms, and, optionally, a heteroatom which<br>
can be N, S, or O;<br>
RB is, independently, H, C1-4 alkyl, cycloalkyl, cycloalkylalkyl, aryl, or<br>
aralkyl;<br>
Z is -CH(OH)CH3 or -CH2NHR1;<br>
Hy is selected from<br>
19<br><br>
20<br>
WO 2006/086600	PCT/US2006/004664<br><br><br>
WO 2006/086600	PCT/US2006/004664<br><br>
R1 is carbocyclyl-C(=O)- or heterocyclyl-C(=O)-, each optionally substituted<br>
with 1, 2 or 3 R3; and<br>
R3 is, independently, selected from C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl,<br>
phenyl, halo, haloalkyl, alkoxy, thialkoxy, amino, alkylamino, dialkylamino,<br>
carboxyl, aIkyl-OC(=O)-5 alkyl-C(=O)-, aryl-OC(=O)-, alkyl-OC(=O)NH-, aryl-<br>
OC(=O)NH-, alkyl-C(=O)NH-, alkyl-C(=O)O-, -OH, -SH, -CN, -N3, -CNO, -CNS,<br>
alkyl-S(=O)-, alkyl-S(=O)2-, H2NS(=O)-, and H2NS(=O)2-.<br>
In some embodiments, compounds of the invention include compounds of<br>
Formula (I)<br>
or pharmaceutically acceptable salt forms thereof, wherein:<br>
Q is -B(ORB)2, boronic acid, or a cyclic boronic ester wherein said cyclic<br>
boronic ester contains from 2 to 20 carbon atoms, and, optionally, a heteroatom which<br>
can be N, S, or O;<br>
RB is, independently, H, C1-4 alkyl, cycloalkyl, cycloalkylalkyl, aryl, or<br>
aralkyl;<br>
Z is -CH(OH)CH3 or -CH2NHR1;<br>
Hy is selected from<br>
21<br><br>
22<br>
WO 2006/086600	PCT/US2006/004664<br><br><br>
WO 2006/086600	PCT/US2006/004664<br><br>
In some embodiments, compounds of the invention include compounds of<br>
Formula (I)<br>
or pharmaceutically acceptable salt forms thereof, wherein:<br>
Q is -B(OH)2 or pinanediol boronic ester;<br>
Z is -CH(OH)CH3 or-CH2NHR];<br>
23<br>
By is selected from<br><br><br>
WO 2006/086600	PCT/US2006/004664<br><br>
In some embodiments, compounds of the invention include compounds of<br>
Formula (I) or phannaceutically acceptable salt forms thereof, wherein:<br>
Q is -B(ORB)2, boronic acid, or a cyclic boronic ester wherein said cyclic<br>
boronic ester contains from 2 to 20 carbon atoms, and, optionally, a heteroatom which<br>
can be N, S, or O;<br>
RB is, independently, H, C1-4 alkyl, cycloalkyl, cycloalkylalkyl, aryl, or<br>
aralkyl;<br>
24<br><br>
WO 2006/086600	PCT/US2006/004664<br>
Z is -CH(OH)CH3;<br>
Hy is a 5- or 6- membered heterocyclic group optionally fused with an aryl or<br>
heteroaryl group, wherein said 5- or 6-membered heterocyclic group contains at least<br>
one ring-forming N atom, and wherein said Hy is optionally substituted by 1,2 or 3<br>
R4;<br>
R4 is, independently, selected from C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, -<br>
OR4a, -SR43, -CN, halo, haloalkyl, -NH2, -NH(alkyl), -N(alkyl)2, -NHC(=O)O-aIkyl, -<br>
NHC(=O)alkyl, -COOH, -C(=O)O-alkyl, -C(=O)alkyl, -C(O)H, -S(=O)-alkyl, -<br>
S(=O)2-alkyl, -S(=O)-aryl, -S(=O)2-aryl, carbocyclyl optionally substituted with 1, 2<br>
or 3 R5, and heterocyclyl optionally substituted with 1, 2 or 3 R5;<br>
R4a is H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, carbocyclyl or<br>
heterocyclyl;<br>
R5 is, independently, selected from C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl,<br>
phenyl, halo, haloalkyl, alkoxy, thialkoxy, amino, alkylamino, dialkylambo,<br>
carboxyl, alkyl-0C(=O)-, alkyl-C(=O)-, aryl-OC(=O)-, alkyl-OC(=O)NH-, aryl-<br>
OC(=O)NH-, alkyl-C(=O)NH-, alkyl-C(=O)O-, -OH, -SH, -CN, -N3, -CNO, -CNS,<br>
alkyl-S(=O)-, alkyl-S(=O)2-, H2NS(=O)-, and H2NS(=O)2-;<br>
25<br>
with the proviso that when Q is<br><br><br>
WO 2006/086600	PCT/US2006/004664<br>
In some embodiments, compounds of the invention include compounds of<br>
Formula (I) or pharmaceutically acceptable salt forms thereof, wherein:<br>
Q is -B(ORB)2, boronic acid, or a cyclic boronic ester wherein said cyclic<br>
boronic ester contains from 2 to 20 carbon atoms, and, optionally, a heteroatom which<br>
can be N, S, or O;<br>
RB is, independently, H, C1-4 alkyl, cycloalkyl, cycloalkylalkyl, aryl, or<br>
aralkyl;<br>
Z is -CH(OH)CH3;<br>
Hy is pyrazine substituted by at least 1 or 2 R4, unsubstituted pyridin-2yl,<br>
pyridin-3-yl optionally substituted by 1 or 2 R4, pyridin-4-yl optionally substituted by<br>
1 or 2 R4, N-oxo-pyridinyl optionally substituted by 1 or 2 R4, pyrimidinyl optionally<br>
substituted by 1 or 2 R4, imidazolyl optionally substituted by 1 or 2 R4, thiazolyl<br>
optionally substituted by 1 or 2 R4, oxazolyl optionally substituted by 1 or 2 R ,<br>
pyrrolyl optionally substituted by 1 or 2 R4, pyrazolyl optionally substituted by 1 or 2<br>
R4, quinolinyl optionally substituted by 1 or 2 R4, isoquinolinyl optionally substituted<br>
by 1 or 2 R4, quinoxalinyl optionally substituted by 1 or 2 R4, indolyl optionally<br>
substituted by 1 or 2 R4, quinazolinyl optionally substituted by 1 or 2 R4,<br>
benzoimidazolyl optionally substituted by 1 or 2 R4, benzothiazolyl optionally<br>
substituted by 1 or 2 R4, or benzoxazolyl optionally substituted by 1 or 2 R4;<br>
R4 is, independently, selected from C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, -<br>
OR4a, -SR4a, -CN, halo, haloalkyl, -NH2, -NH(alkyl), -N(alkyl)2, -NHC(=O)O-alkyl, -<br>
NHC(=O)alkyl, -COOH, -C(=O)O-aIkyI, -C(=O)alkyI, -C(O)H, -S(=O)-alkyl, -<br>
S(=O)2-alkyl, -S(=O)-aryl, -S(=O)2-aryl, carbocyclyl optionally substituted with 1, 2<br>
or 3 R5, and heterocyclyl optionally substituted with 1,2 or 3 R5;<br>
R4a is H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, carbocyclyl or<br>
heterocyclyl; and<br>
R5 is, independently, selected from C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl,<br>
phenyl, halo, haloalkyl, alkoxy, thialkoxy, amino, alkylamino, dialkylamino,<br>
carboxyl, alkyl-OC(=O)-, alkyl-C(=O)-, aryl-OC(=O)-, alkyl-OC(=O)NH-, aryl-<br>
26<br><br>
WO 2006/086600	PCT/US2006/004664<br>
OC(=O)NH-, alkyl-C(=O)NH-, alkyl-C(=O)O, -OH, -SH, -CN, -N3, -CNO, -CNS,<br>
alkyl-S(K))-, alkyl-S(=O)2-, H2NS(=O)-, and H2NS(=O)2-.<br>
In some embodiments, compounds of the invention include compounds of<br>
Formula (I) or pharmaceutically acceptable salt forms thereof, wherein:<br>
Q is -B(ORB)2, boronic acid, or a cyclic boronic ester wherein said cyclic<br>
boronic ester contains from 2 to 20 carbon atoms, and, optionally, a heteroatom which<br>
can be N, S, or O;<br>
RB is, independently, H, C1-4 alkyl, cycloalkyl, cycloalkylalkyl, aryl, or<br>
aralkyl;<br>
Z is -CH(OH)CH3;<br>
Hy is pyrazine substituted by at least 1 or 2 R4, unsubstituted pyridin-2yl,<br>
pyridin-3-yl optionally substituted by 1 or 2 R4, pyridin-4-yl optionally substituted by<br>
1 or 2 R4, N-oxo-pyridinyl optionally substituted by 1 or 2 R4, pyrimidinyl optionally<br>
substituted by 1 or 2 R4, imidazolyl optionally substituted by 1 or 2 R4, thiazolyl<br>
optionally substituted by 1 or 2 R4, pyrazolyl optionally substituted by 1 or 2 R4,<br>
quinolinyl optionally substituted by 1 or 2 R4, isoquinolinyl optionally substituted by<br>
1 or 2 R4, quinoxalinyl optionally substituted by 1 or 2 R4, or indolyl optionally<br>
substituted by 1 or 2 R4;<br>
R4 is, independently, selected from C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, -<br>
OR4a, -SR4a, -CN, halo, haloalkyl, -NH2, -NH(alkyl), -N(alkyl&gt;2, -NHC(=O)O-alkyl, -<br>
NHC(=O)alkyl, -COOH, -C(=O)O-alkyl, -C(=O)alkyl, -C(O)H, -S(=O)-alkyl, -<br>
S(=O)2-aIkyl, -S(=O)-aryl, -S(=O)2-aryl, carbocyclyl optionally substituted with 1, 2<br>
or 3 R5, and heterocyclyl optionally substituted with 1,2 or 3 R5;<br>
R4a is H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, carbocyclyl or<br>
heterocyclyl; and<br>
R5 is, independently, selected from C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl,<br>
phenyl, halo, haloalkyl, alkoxy, thialkoxy, amino, alkylamino, dialkylamino,<br>
carboxyl,  alkyl-OC(=O)-,  alkyl-C(=O)-,  aryl-OC(=O)-,  alkyl-OC(=O)NH-,  aryl-<br>
27<br><br>
WO 2006/086600	PCT/US2006/004664<br>
OC(=O)NH-, alkyl-C(=O)NH-, alkyl-C(O)0-,  -OH, -SH, -CN, -N3, -CNO, -CNS,<br>
alkyl-S(=O)-, aIkyl-S(=O)2-, H2NS(=O)-, and H2NS(=O)2-.<br>
In some embodiments, compounds of the invention include compounds of<br>
Formula (I) or pharmaceutically acceptable salt forms thereof, wherein:<br>
Q is -B(ORB)2, boronic acid, or a cyclic boronic ester wherein said cyclic<br>
boronic ester contains from 2 to 20 carbon atoms, and, optionally, a heteroatom which<br>
can be N, S, or O;<br>
RB is, independently, H, C1-4 alkyl, cycloalkyl, cycloalkylalkyl, aryl, or<br>
aralkyl;<br>
Z is -CH(OH)CH3; and<br>
28<br>
Hy is selected from<br><br><br>
WO 2006/086600	PCT/US2006/004664<br><br>
29<br>
In some embodiments, compounds of the invention include compounds of<br>
Formula (I) or pharmaceutically acceptable salt forms thereof, wherein:<br>
Q is -B(OH)2 or pinanediol boronic ester;<br>
Z is -CH(OH)CH3; and<br>
Hy is selected from<br><br><br>
WO 2006/086600	PCT/US2006/004664<br><br>
In some embodiments, compounds of the invention include compounds of<br>
Formula (I) or pharmaceutically acceptable salt forms thereof, wherein:<br>
Q is -B(ORB)2, boronic acid, or a cyclic boronic ester wherein said cyclic<br>
boronic ester contains from 2 to 20 carbon atoms, and, optionally, a heteroatom which<br>
can be N, S, or O;<br>
30<br><br>
The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly or indirectly with proteasome activity.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI3MjYta29sbnAtMjAwNy1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">02726-kolnp-2007-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI3MjYta29sbnAtMjAwNy1hc3NpZ25tZW50LnBkZg==" target="_blank" style="word-wrap:break-word;">02726-kolnp-2007-assignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI3MjYta29sbnAtMjAwNy1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">02726-kolnp-2007-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI3MjYta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">02726-kolnp-2007-correspondence others 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI3MjYta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMgMS4yLnBkZg==" target="_blank" style="word-wrap:break-word;">02726-kolnp-2007-correspondence others 1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI3MjYta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">02726-kolnp-2007-correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI3MjYta29sbnAtMjAwNy1kZXNjcmlwdGlvbiBjb21wbGV0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">02726-kolnp-2007-description complete.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI3MjYta29sbnAtMjAwNy1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">02726-kolnp-2007-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI3MjYta29sbnAtMjAwNy1mb3JtIDIucGRm" target="_blank" style="word-wrap:break-word;">02726-kolnp-2007-form 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI3MjYta29sbnAtMjAwNy1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">02726-kolnp-2007-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI3MjYta29sbnAtMjAwNy1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">02726-kolnp-2007-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI3MjYta29sbnAtMjAwNy1ncGEucGRm" target="_blank" style="word-wrap:break-word;">02726-kolnp-2007-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI3MjYta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHB1YmxpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">02726-kolnp-2007-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI3MjYta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHNlYXJjaCByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">02726-kolnp-2007-international search report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI3MjYta29sbnAtMjAwNy1wY3QgcmVxdWVzdCBmb3JtLnBkZg==" target="_blank" style="word-wrap:break-word;">02726-kolnp-2007-pct request form.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI3MjYta29sbnAtMjAwNy1wcmlvcml0eSBkb2N1bWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">02726-kolnp-2007-priority document.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LSgyMy0wNy0yMDEyKS1BQlNUUkFDVC5wZGY=" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-(23-07-2012)-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LSgyMy0wNy0yMDEyKS1BTUFOREVEIENMQUlNUy5wZGY=" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-(23-07-2012)-AMANDED CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LSgyMy0wNy0yMDEyKS1BTk5FWFVSRSBUTyBGT1JNIDMucGRm" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-(23-07-2012)-ANNEXURE TO FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LSgyMy0wNy0yMDEyKS1ERVNDUklQVElPTiAoQ09NUExFVEUpLnBkZg==" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-(23-07-2012)-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LSgyMy0wNy0yMDEyKS1FWEFNSU5BVElPTiBSRVBPUlQgUkVQTFkgUkVDRUlWRUQucGRm" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-(23-07-2012)-EXAMINATION REPORT REPLY RECEIVED.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LSgyMy0wNy0yMDEyKS1GT1JNLTEucGRm" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-(23-07-2012)-FORM-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LSgyMy0wNy0yMDEyKS1GT1JNLTIucGRm" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-(23-07-2012)-FORM-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LSgyMy0wNy0yMDEyKS1PVEhFUlMucGRm" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-(23-07-2012)-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LSgyMy0wNy0yMDEyKS1QRVRJVElPTiBVTkRFUiBSVUxFIDEzNy5wZGY=" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-(23-07-2012)-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LSgyNi0wOS0yMDEyKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-(26-09-2012)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LUFTU0lHTk1FTlQucGRm" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-ASSIGNMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LUNBTkNFTExFRCBQQUdFUy5wZGY=" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-CANCELLED PAGES.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LUVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1rb2xucC0yMDA3LWZvcm0gMTgucGRm" target="_blank" style="word-wrap:break-word;">2726-kolnp-2007-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LUZPUk0gMjYucGRm" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-FORM 26.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LUdSQU5URUQtQUJTVFJBQ1QucGRm" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-GRANTED-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LUdSQU5URUQtQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-GRANTED-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LUdSQU5URUQtREVTQ1JJUFRJT04gKENPTVBMRVRFKS5wZGY=" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-GRANTED-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LUdSQU5URUQtRk9STSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-GRANTED-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LUdSQU5URUQtRk9STSAyLnBkZg==" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-GRANTED-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LUdSQU5URUQtRk9STSAzLnBkZg==" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-GRANTED-FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LUdSQU5URUQtRk9STSA1LnBkZg==" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-GRANTED-FORM 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LUdSQU5URUQtU1BFQ0lGSUNBVElPTi1DT01QTEVURS5wZGY=" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-GRANTED-SPECIFICATION-COMPLETE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LU9USEVSUy5wZGY=" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LVBFVElUSU9OIFVOREVSIFJVTEUgMTM3LnBkZg==" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjcyNi1LT0xOUC0yMDA3LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">2726-KOLNP-2007-REPLY TO EXAMINATION REPORT.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="256131-method-for-the-anonymous-authentication-of-a-data-transmitter.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="256133-polyolefin-composition-comprising-a-crosslinkable-polyolefin-and-the-silanol-condensation-catalyst-and-masterbatch-for-such-composition.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>256132</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>2726/KOLNP/2007</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>19/2013</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>10-May-2013</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>07-May-2013</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>24-Jul-2007</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>CEPHALON, INC</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>41. MOORES ROAD P.O. BOX 4011 FRAZER, PENNSYLVANIA</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>RAFFAELLA BERNARDNINI</td>
											<td>VIA NICOSIA, 2 I-56011 CALCI</td>
										</tr>
										<tr>
											<td>2</td>
											<td>AMBROGIO OLIVA</td>
											<td>VIA VISCONTI, 27 I-21047 SARONNO</td>
										</tr>
										<tr>
											<td>3</td>
											<td>GERMANO D&#x27;ARASMO</td>
											<td>VIA ALESSANDRO VOLTA, 9 I-20026 NOVATE MILANESE</td>
										</tr>
										<tr>
											<td>4</td>
											<td>PAOLO G. CASSARA</td>
											<td>VIA OSLAVIA, 25 I-20052 MONZA</td>
										</tr>
										<tr>
											<td>5</td>
											<td>ALBERTO BERNAREGGI</td>
											<td>VIA ADIGE, 25 I-20049 CONCOREZZO</td>
										</tr>
										<tr>
											<td>6</td>
											<td>ERNESTO MENTA</td>
											<td>VIA FRANCESCO BARACCA, 7 I-20063 CERNUSCO SUL NAVIGLIO</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07F 5/02,A61P 35/00</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/US2006/004664</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2006-02-10</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>60/652,370</td>
									<td>2005-02-11</td>
								    <td>U.S.A.</td>
								</tr>
								<tr>
									<td>2</td>
									<td>11/351,193</td>
									<td>2006-02-09</td>
								    <td>U.S.A.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/256132-proteasome-inhibitors-and-methods-of-using-the-same by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 09:53:22 GMT -->
</html>
